Sign In
  • A-
  • A
  • A+
  • ع
  • A-
  • A
  • A+
  • ع
Prof.Wael M. Abdel-Rahman Hassan Professor, Coordinator of MSc/PhD program in Molecular Medicine Academic RankProfessor


  • Molecular Pathology

Research Interests:

  • Cancer Research: 1. Environmental causes of cancer. 2. Molecular basis of cancer development by environmental toxins, and/or obesity 3. Molecular genetics of colon & breast cancer, microRNA, impact of molecular changes on response to therapy 4. Familial Cancer syndromes 5. Methylation and environment in tumor development


1- Ph.D., Molecular Pathology, Edinburgh University, UK, 2001 2- Histopathology M.Sc., Pathology/Histopathology, Zagazig University, Egypt, 1995 3- M.D. (M. B., B. CH.), Faculty of Medicine, Zagazig University, Egypt, 1989
1. September 2013 - Till present: Coordinator, MSc/PhD program in Molecular Medicine and Translational Research, College of Medicine, University of Sharjah 2. January 2011- Till present: Associate Professor, University of Sharjah, College of Health Sciences, M.L.S., Sharjah, U.A.E. 3. September 2007 –December 2010: Assistant Professor, University of Sharjah, College of Health Sciences, M.L.T., Sharjah, U.A.E. 4. January 2002 – September 2007: • Senior Scientist & Molecular Pathologist, Department of Medical Genetics, Biomedicum Helsinki, University of Helsinki, Finland. • Assistant Professor (Lecturer in Egyptian System), Pathology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt. 5. April, 2001 – December, 2001: Lecturer (Assistant Lecturer in Egyptian System), Pathology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt 6. January, 1999 – March, 2001: Research Fellow, Pathology Department, University of Cambridge, Cambridge, UK. 7. May, 2000 –March, 2001: Honorary Specialist Registrar, Department of Histopathology, Waldenbooks’ Hospital, Cambridge, UK. 8. January, 1997 – January, 1999: Research Fellow, Department of Pathology, Faculty of Medicine, University of Edinburgh, Edinburgh, UK. 9. 1995-1997 Lecturer, Pathology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt. 10. 1991-1995 Demonstrator, Pathology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt. 11. 1990 -1991: Internship (House Officer). Zagazig University Hospitals, Egypt
Sept 2013 till present UAE UoS Program coordinator, MSc Molecular Medicine 2007 2002 Finland University of Helsinki, Finland. Senior Scientist 2001 1999 United Kingdom University of Cambridge Research Fellow 2001 2000 United Kingdom Adenbrooks’ Hospital, Cambridge Honorary Specialist Registrar 1997 1997 United Kingdom University of Edinburgh Research Fellow 1991 1990 Egypt Military clinics and Ministry of Health Physician 1990 1989 Egypt Zagazig University Hospitals House Officer, , Zagazig, Egypt
Professional Memberships 1. The European association for Cancer Research. 2. The American Association for Cancer Research. 3. The Asian Pacific Society for Cancer Prevention 4. The Egyptian Medical Syndicate. The Egyptian Society for Pathologists Editorial Boards 1. Editorial Board Member of World J of Gastrointestinal Oncology, Baishiding, China 2. Editorial Board Member of SciTz Clinical and Medical Oncology, USA 3. Editorial Board Member of SRL Oncology & Hematology, USA 4. Editorial Board Member of Hamdan Medical Journal, UAE. 5. Editorial Board Member of America Journal of Molecular Biology, USA. 6. Editorial Board Member of International Journal of Medical Biotechnology & Genetics (IJMBG), SCiDoc publisher Delaware, USA 7. Molecular Medicine open Access
1. University of Sharjah - University Research Board (URB) . Molecular Study of Colon and Breast Cancer Development in Obesity (PI) fund of AED 200,000, Nov., 2016 -2019 2. University Research Board (URB) -Investigating the impact of ShcD in melanoma migration and survival via ROS modulation. PI Dr Samrein Ahmed. 200 000. Nov, 2016 – 2018. 3. University of Sharjah, University Research Board (URB) Mitochondrial and Metabolic Gene Profiling of Ramadan Intermittent Fasting in Metabolic Syndrome Patients, (PI Dr Moez Al Islam) 200 000. Nov, 2016 - 2018 4. Boehringer Ingelheim- UoS Award (PI) Elucidation of cell death mechanisms of novel molecules CP-380736 and MPT-0B014 in colorectal and breast cancer. 11.500 AED, 2017. 5. Coordinator of Research group University of Sharjah. “Environment and cancer research group”. Annual budge – Operational grant only 120 000 AED, Sept 2016 – Sept 2017. 6. Al Jalila Foundation (co-investigator, PI Dr Samrein Ahmed) Studying the phosphorylation status of ShcD in melanoma upon oxidative stress: An evidence for new therapeutic target in melanoma. Budget: 270,000AED, Jan 2017 - 2019. 7. Boehringer Ingelheim- UoS Award (PI) Predicting Colorectal Cancer Risk in Subjects with Metabolic Syndrome in University of Sharjah Community. 15 000 AED 2016. 8. Boehringer Ingelheim- UoS Award (co-PI) Significance of Galanin expression on caspase 8 –mediated apoptosis and sensitivity to chemotherapy in colon cancer cells. 15 000 AED 2016. 9. University of Sharjah, (PI), interdisciplinary grant 135000 AED. Bisphenol A and colorectal carcinogenesis. Sep 2015 - 2017 10. Sheikh Hamdan Bin Rashid Al Maktoum Medical Award- Optimizing the differentiation of human induced plueripotent stem cells derived from diabetic patients towards insulin secreting beta cells of pancreas. 167,500 AED, 2015 (co-investigator). 11. Sheikh Hamdan Bin Rashid Al Maktoum Medical Award- Bone Regeneration for Dental Transplantation. . 100,000 AED, 2015 (co-investigator). 12. Study the Molecular Changes Associated with the Dietary Chemoprevention of Camel Milk (Camelus dromedarius) against Azoxymethane-Induced Colorectal Cancer in Fischer 344 Rat Model. Coinvestigator. UoS. 13. Al Jalila Foundation – PI- Molecular Mechanisms of carcinogenesis by environmental toxins 2014 -2016 14. Boehringer Ingelheim- UoS Award (PI) 1-VEGF-c and response to antiangiogenic therapy in relation to the mismatch repair status of colorectal cancers. 15. Boehringer Ingelheim- UoS Award (PI) 2- HIF-1α and response to antiangiogenic therapy in relation to the p53 status of breast and colorectal cancers. 16. Terry Fox Foundation grant for cancer research (P.I.) 400 000,00 AED 2012-2015
1. Farheen Alam, Fatima Mezhal, Hussain EL Hasasna, Vidhya A Nair, Aravind S.R., Maha Saber Ayad, Ahmed El-Serafi, Wael M Abdel-Rahman. The role of p53-microRNA 200-Moesin axis in invasion and drug resistance of breast cancer cells. Tumor Biology, 2017 2. Wael M Abdel-Rahman, Noura A. Al-khayyal, Vidhya A Nair, Aravind S.R., Maha Saber-Ayad. Role of AXL in invasion and drug resistance of colon and breast cancer cells and its association with p53 alterations. World J Gastroenterology. 2017, 23(19):3440-3448. 3. Abdel-Rahman WM, Faris ME, Peltomäki P. Molecular determinants of colon cancer susceptibility in the East and West. Curr Mol Med. 2017, 17:34-45. 4. Abdel-Rahman WM, Lotsari-Salomaa JE, Kaur S, Niskakoski A, Knuutila S, Järvinen H, Mecklin JP, Peltomäki P. The Role of Chromosomal Instability and Epigenetics in Colorectal Cancers Lacking beta-Catenin/TCF Regulated Transcription. Gastroenterology Research and Practice. 2016 Vol 2016: 1-11 Article ID 6089658. 5. Joensuu EI, Nieminen TT, Lotsari JE, Pavicic W, Abdel-Rahman WM, Peltomäki P. Methyltransferase expression and tumor suppressor gene methylation in sporadic and familial colorectal cancer. Genes Chromosomes Cancer. 2015 Dec;54(12):776-87. 6. Nieminen TT, O'Donohue MF, Wu Y, Lohi H, Scherer SW, Paterson AD, Ellonen P, Abdel-Rahman WM, Valo S, Mecklin JP, Järvinen HJ, Gleizes PE, Peltomäki P. Germline Mutation of RPS20, Encoding a Ribosomal Protein, Causes Predisposition to Hereditary Nonpolyposis Colorectal Carcinoma Without DNA Mismatch Repair Deficiency. Gastroenterology 2014 Sep;147(3):595-598.e5. 7. Abdel-Rahman WM, Nieminen TT, Shoman S, Eissa S, Peltomäki P. Loss of p15INK4b Expression in Colorectal Cancer is Linked to Ethnic Origin. Asian Pacific Journal for Cancer Prevention. 2014;15(5):2083-2087. 8. Abdel-Rahman WM, Moustafa YM, Ahmed BO, Mostafa RM. Endocrine disruptors and breast cancer risk – time to consider the environment. Asian Pacific Journal for Cancer Prevention. 2012 13(12) 5937-5946 9. Saleh EM, El-Awady RA, Eissa NA, Abdel-Rahman WM. Antagonism between curcumin and the topoisomerase II inhibitor etoposide: A study of DNA damage, cell cycle regulation and death pathways. Cancer Biol Ther. 2012 Sept; 13(11):1058-1071. 10. Abdel-Rahman W M, Ruosaari S, Knuutila S, P Peltomäki. Differential roles of EPS8 in carcinogenesis: Loss of protein expression in a subset of colorectal carcinoma and adenoma. World Journal of Gastroenterology. 2012 Aug 7;18(29):3896-903. 11. Lotsari JE, Gylling A, Abdel-Rahman WM, Nieminen TT, Aittomäki K, Friman M, Pitkänen R, Aarnio M, Järvinen HJ, Mecklin JP, Kuopio T, Peltomäki P. Breast carcinoma and Lynch syndrome: molecular analysis of tumors arising in mutation carriers, non-carriers, and sporadic cases. Breast Cancer Res. 2012 Jun 12;14(3):R90. 12. Carlsson E, Ranki A, Sipilä L, Karenko L, Abdel-Rahman WM, Ovaska K, Siggberg L, Aapola U, Assämäki R, Häyry V, Niiranen K, Helle M, Knuutila S, Hautaniemi S, Peltomäki P, Krohn K. Potential role of a navigator gene NAV3 in colorectal cancer. Br J Cancer. 2012 Jan 31;106(3):517-24. 13. Nieminen TT, Shoman S, Eissa S, Peltomäki P, Abdel-Rahman WM. Distinct Genetic and Epigenetic Signatures of Colorectal Cancers According to Ethnic Origin. Cancer Epidemiol Biomarkers Prev. 2012 Jan;21(1):202-11. 14. Nieminen TT, Abdel-Rahman WM, Ristimaki A, Lappalinen M, Lahermo P, Mecklin JP, Järvinen HJ, Peltomäki P. BMPR1A mutatins in herditary nopolyposis colorectal cancer without mismatch repair deficiency. Gastroenterology, 2011 Jul;141(1):e23-6. 15. Nieminen TT, Gylling A, Abdel-Rahman WM, Nuorva K, Aarnio M, Renkonen-SinisaloL, Järvinen HJ, Mecklin JP, Bützow R, Peltomäki P. Molecular analysis of endometrial tumorigenesis: importance of complex hyperplasia regardless of atypia. Clin Cancer Res. 2009;15(18):5772-83. 16. Abdel-Rahman WM. Genomic instability and carcinogenesis: an update. Current Genomics 2008, 9:535-541 17. Abdel-Rahman WM, Peltomäki P. Lynch syndrome and related familial colorectal cancers. Crit Rev Oncog. 2008;14(1):1-22 18. Joensuu EI, Abdel-Rahman WM, Ollikainen M, Ruosaari S, Knuutila S, Peltomäki P., Epigenetic signatures of familial cancer are characteristic of tumor type and family category. Cancer Research 2008 Jun 15;68(12):4597-605. 19. Gylling AH, Nieminen TT, Abdel-Rahman WM, Nuorva K, Juhola M, Joensuu EI, Järvinen HJ, Mecklin JP, Aarnio M, Peltomäki PT. Differential cancer predisposition in Lynch syndrome: insights from molecular analysis of brain and urinary tract tumors. Carcinogenesis. 2008 Jul;29(7):1351-9. 20. Hahtola S, Burghart E, Jeskanen L, Karenko L, Abdel-Rahman WM, Polzer B, Kajanti M, Peltomäki P, Pettersson T, Klein CA, Ranki A. Clinicopathological characterization and genomic aberrations in subcutaneous panniculitis-like T-cell lymphoma. J Invest Dermatol. 2008 Sep;128(9):2304-9. 21. Abdel-Rahman WM, Kalinina J, Shoman S, Eissa S,Ollikainen M, Elomaa O, Eliseenkova A, Bützow R, Mohammadi M, Peltomäki P. Somatic mutations of FGF9 in colorectal and endometrial carcinomas,(2008) Human Mutation, 29(3):390-397. 22. Abdel-Rahman WM, Peltomäki P, Knuutila S, Harrison DJ, Bader SA. Truncation of MBD4 predisposes to reciprocal chromosomal translocations and alters the response to therapeutic agents. (2008) DNA Repair 7:321-328. 23. Hahtola S, Burghart E, Puputti M, Karenko L, Abdel-Rahman WM, Väkevä L, Jeskanen L, Virolainen S, Karvonen´J, Salmenkivi K, Kinnula V, Joensuu H, Peltomäki P, Klein C, Ranki AM. Cutaneous T-cell lymphoma-associated lung cancer show chromosomal abberations differing from primary lung cancer. (2008) Genes Chromsomes and Cancer, 47:107-117. 24. Ollikainen M, Gylling A, Nupponen N, Abdel-Rahman WM, Butzow R, Peltomäki P. Patterns of PIK3CA alterations in familial colorectal and endometrial carcinoma. (2007), International Journal of Cancer. 121(4):915-920. 25. Gylling A, Abdel-Rahman WM, Juhola M, Nuorva K, Hautala E, Jarvinen HJ, Mecklin JP, Aarnio M, Peltomaki P. (2007). Is gastric cancer part of the tumor spectrum of hereditary nonpolyposis colorectal cancer? - A molecular genetic study.Gut. 56(7):926-933 26. Ollikainen M, Hannelius U, Lindgren CM, Abdel-Rahman WM, Kere J, Peltomaki P. Mechanisms of inactivation of MLH1 in hereditary nonpolyposis colorectal carcinoma: a novel approach. Oncogene. 2007 26(31):4541-4549. 27. Abdel-Rahman WM. Mutations of β-catenin and KRAS in colorectal carcinomas. Digestive Diseases and Sciences (2006) 51(3):616-617. 28. Abdel-Rahman WM, Mecklin JP., Peltomäki P. (2006) The genetics of HNPCC: application to diagnosis and screening. Critical Reviews in Oncology/Haematology 58:208-220 29. Renkonen E, Nieminen P, Abdel-Rahman WM, Moisio A-L, Järvela I, Arte S, Järvinen HJ, Peltomäki P. Adenomatous polyposis families that screen APC mutation negative are genetically heterogenous. Journal of Clinical Oncology 2005;23(24):5651-9. 30. Ollikainen M, Abdel-Rahman WM, Moisio A-L, Lindroos A, Kariola R, Jarvela I, Poyhonen M, Butzow R, Peltomäki P. (2005) Molecular analysis of familial endometrial carcinoma: a manifestation of hereditary non-polyposis colorectal cancer or a separate syndrome. Journal of Clinical Oncology 23(21):4609-4616. 31. Kariola R, Abdel-Rahman WM (equal contribution), Ollikainen M, Butzow R, Nyström M, Peltomäki P. (2005) APC and beta-catenin protein expression patterns in HNPCC- related endometrial and colorectal cancers. Familial Cancer 4(2):187-90. 32. Abdel-Rahman W M. (2005) Multiple reciprocal translocations in carcinomas. Cancer Genetics & Cytogenetics, 158:194-195. 33. Abdel-Rahman WM, Ollikainen M, Kariola R, Järvinen H, Mecklin J-P, Nyström-Lahti M, Knuutila S, Peltomäki P. (2005) Comprehensive characterization of HNPCC-related colorectal cancers reveals striking molecular features in families with no germline mismatch repair gene mutations. Oncogene, 24:1542-1551. 34. Abdel-Rahman WM, Lohi H., Knuutila S., and Peltomäki P. (2005) Restoring mismatch repair does not stop the formation of reciprocal translocations in the colon cancer cell line HCA7 but further destabilizes chromosome number. Oncogene 24:706-713. 35. Abdel-Rahman WM and Peltomäki P. (2004) Molecular basis and diagnostics of hereditary colorectal cancers. Annals of Medicine, 36: 379-388 36. Raevaara TE, Gerdes AM, Lonnqvist KE, Tybjaerg-Hansen A, Abdel-Rahman WM, Kariola R, Peltomäki P, and Nyström-Lahti M. (2004) HNPCC mutation MLHI P648S makes the functional protein unstable, and homozygosity predisposes to mild neurofibromatosis type 1. Genes Chromosomes & Cancer, 40: 261-265. 37. Renkonen E, Zhang Y, Lohi H, Salovaara R, Abdel-Rahman WM, Nilbert M, Aittomäki K, Järvinen HJ, Mecklin J-P, Lindblom A, Peltomäki P. (2003) Altered expression of MLH1, MSH2 and MSH6 in predisposition to hereditary nonpolyposis colorectal cancer. Journal of Clinical Oncology 21:3629-37. 38. Raevaara TE, Vaccaro C, Abdel-Rahman WM, Mocetti E, Bala S, Lönnqvist KE, Kariola R, Lynch HT, Peltomäki P, Nyström-Lahti M (2003) Pathogenicity of the hereditary colorectal cancer mutation hMLH1 del616 linked to shortage of the functional protein. Gastroenterology 125:501-509. 39. Abdel-Rahman WM, Katsura K, Rens W, Gorman PA, Sheer D, Bicknell D, Bodmer WF, Arends MJ, Wyllie AH, Edwards PAW (2001). Spectral karyotyping suggests additional subsets of colorectal cancers characterized by pattern of chromosome rearrangement. Proceedings of the National Academy of Sciences USA 98: 2538-2543. 40. Abdel-Rahman WM, Georgiades IB, Curtis LJ, Arends MJ and Wyllie AH. (1999). Role of BAX mutations in mismatch repair-deficient colorectal carcinogenesis. Oncogene 18:2139-2142. 41. Abdel-Rahman WM, Arends MJ, Morris RG, Ramadan ME, Wyllie AH. (1999). Death pathway genes Fas (Apo-1/CD95) and Bik (nbk) show no mutations in colorectal carcinomas. Cell Death and Differentiation 6:387-388
Supervised and co-supervised > 15 MSc & PhD students at University of Sharjah (Main supervisor) & University of Helsinki (co-supervisor). Supervised and co-supervised > 30 undergraduate student projects at University of Sharjah
Two Finnish and International patents on use of NAV3 as diagnostic tool in colon cancer – Methods and uses involving genetic abnormalities at chromosome 12.
1. Best Undergraduate Student Poster Award, 11th Research Forum 2017, University of Sharjah, UAE 2. Best research poster prize, Sheikh Hamdan Bin Rashid Al Maktoum Award for Medical Sciences, The 9th Dubai International Conference for Medical Sciences, 14-16 December 2016, media report Published in Al Bayan newspaper 17 Dec 2016. 3. Full page Media report “Cancer’s Environmental triggers” in “The National” Newspaper, 15 Jan 2015. 4. Annual Incentive Award – Teaching and academic performance, University of Sharjah, 2016 5. Annual Incentive Award – Research, 2015. University of Sharjah, Sharjah , UAE 6. Prize for Panel member contribution at Al Jalila Foundation meeting 2014 7. The Best Presentation at MedLab Conference, Arab Health, Dubai, UAE, 24-27 Jan., 2011 8. Annual Incentive Award – Research, University of Sharjah, 2010 9. Best research paper prize, 5th Annual Scientific Research Forum, UoS., University of Sharjah,, April 2009 10. Two Finnish and International patents on use of NAV3 as diagnostic tool in colon cancer – Methods and uses involving genetic abnormalities at chromosome 12. 11. Most common cited article Prize- Critical Review Oncology/Hematology, El Sevier Publisher, 2006- 2008. 12. Best research paper prize, 4th Annual Scientific Research Forum, UoS, University of Sharjah, 7th-8th May 2008. 13. Inclusion as a Biographee in Who's Who in the World. Marquis Who's Who, NJ, USA & Top 100, Cambridge, UK as well as Top 100 and other databases.
1. Member of the University of Sharjah Post Graduate Council since 2012 till present 2. Chair of College of Health Sciences Research & Postgraduate studies Committee 2014 till present. 3. Honorary member of College of Medicine Research Committee 2015/2016. 4. Scientific Advisory Board – Sharjah Institute for Medical Research, Sharjah, UAE. 2014 -2016 5. Chair and member of > 20 selection/recruitment committees for appointing Professors, Lectures & technicians at College of Health Sciences. 6. Chair and member of > 12 selection committee for appointing research assistants and postdoctoral researchers, Senior scientists at Sharjah Institute for Medical Research (SIMR). 7. Member of >5 promotion committees at College of Health Sciences, University of Sharjah. 8. A member of UoS representatives at Halal Conferences, Prince Sigkola University, Thailand 2014. 9. Panel member: The challenges and opportunities in biomedical research in the region, Al-Jalila Foundation meeting, Dubai, 2014 10. MoH license examination committee - member, Ministry of Health, Dec 2013 11. Members of the University of Sharjah Ethics Committee 2010 till 2014. 12. Lecture on ‘ Research Fund applications”, College of Health Sciences faculty members, 23 Oct 2014 13. CME Lectures at Saqer Hospital , RAK Nov., 2012 (7 CME points) 14. Member of UAE/MOH task force for Legislating stem cell therapy and applications in UAE 2012. 15. A Key member of the founding/advising committee of the new “International Sharjah Biomedical Research Center” at the Sharjah Medical Excellence Cluster (SMEC), Medical Colleges campus, to serve UAE community and Research group leader. 16. Judge of Intel Science competition/Arab World 2011 & 2012. 17. Magazine Article in MedLab magazine, Molecular diagnosis of familial colorectal cancers – Where are we, issue 1-2011 18. Contribution to the annual Cancer Awareness Days at University of Sharjah 19. CME public Lecture on: Familial Colorectal Cancer Medical Campus and University hospital, UoS1-Mar-11. 20. Public Lecture on: Breast Cancer prevention & diagnosis, Khorfakan branch of UoS, 10-Feb-11 21. Member of the Student Affairs and Academic Advising, a CHS College level committee, since 2009 till present. 22. Member of the College Council – CHS. Since 2009 till 2011, then 2015/2016. 23. Invited Lecture at the ‘World Cancer Congress’ an International meeting, delivered a talk on ‘familial colorectal cancers’ 23-26 June 2009, Beijing, China. 24. Member and repertoire of the Student Assessment Committee ‘SAC”; College level committee, academic year 2008/2009, CHS. 25. Adhoc –Subcommittee- on Course Alignment Biology, Anatomy & Physiology, Pathophysiology; College level committee. Member & meeting repertoire; Jan 2009; Jan 2009 26. Activity in UoS Open Days aimed at potential students, UoS,14-25th April 27. Presentation at 1st Emirates Pathologist Meeting entitled “Applications of Immunohistochemistry in Hereditary Cancer Diagnosis”, audience Emirates Pathologists. meeting at UoS College of Medicine,1st March 2008 28. Collaboration with National Cancer Institute, Egypt on the study of young age cancers serving Egyptian and international community, 2007 - ongoing 29. Ongoing collaboration with Department of Medical Genetics, Helsinki University, Finland, to serve the international community on cancer management. Ongoing 30. Chair and member of many Adhoc committees for - Evaluation of research projects submitted for Sharjah Islamic Bank, “Dana Gas” Prize,. Tanmeyat” Prize, ...ect 31. Member of MLT Strategic planning - research committee ,College level, committee member, Spring 2008,Spring 2008
I teach a variety of courses at both undergraduate and post-graduate levels. A unifying aim in all of these is striving to ensure that students learn the fundamental content of the courses and/or master the laboratory techniques which I teach. Equally important is to facilitate the acquisition of lifelong learning skills and to foster critical thinking skills to prepare students to function as highly skilled professionals. My teaching philosophy is based on two principles, which are supported extensively in the literature: (a) active student learning strongly influences student-learning outcomes; and (b) assessment procedures strongly influence student acquisition of knowledge.
Back to list